# Larimar Therapeutics (LRMR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/LRMR
## Company Profile
- Ticker: LRMR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.37 USD
- Market cap: 342813692.09999996 USD
- Last updated: 2026-08-12
## Business Overview
### Intracellular Protein Delivery
Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin.
### Nomlabofusp
Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia. The therapy is intended to address the underlying protein deficiency rather than only manage disease symptoms.
### Accelerated-Approval Strategy
Larimar is working with the FDA on a BLA using skin frataxin as a biomarker and matched natural-history comparisons for clinical outcomes. A global confirmatory Phase 3 trial is planned to be underway at submission and uses change in the Upright Stability Score as its primary endpoint.
### Platform Expansion
Beyond Friedreich’s ataxia, Larimar intends to use its intracellular delivery technology to create fusion proteins for other rare diseases caused by deficiencies in intracellular bioactive compounds.
## Why The Stock Is Moving

As of Aug 12, 2026, LRMR closed up 1.39% at $4.37. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline open-label nomlabofusp data expected in the second quarter of 2026.
- Start of screening for the confirmatory Phase 3 study expected in the second quarter of 2026, with first dosing around mid-2026.
- Nomlabofusp BLA submission seeking accelerated approval planned for June 2026.
- Potential U.S. launch targeted for the first half of 2027, subject to approval.

## Recent News
- 2026-08-04 11:00 EST — [Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-second-quarter-2026-financial-and-business-update-a986353a) — Source: Larimar Therapeutics
- 2026-06-29 10:30 EST — [Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-positive-open-label-data-and-submission-of-first-mo-5e1889f2) — Source: Larimar Therapeutics
- 2026-06-26 20:05 EST — [Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-fri-42a5b003) — Source: Larimar Therapeutics
- 2026-05-14 11:00 EST — [Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update) — Source: Larimar Therapeutics
- 2026-04-30 20:05 EST — [Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-publishes-cross-species-findings-supporting-skin-as-a-surrogate-for-the-measurement-of-frataxin-in-tissues-clinically-relevant-to-friedreich-s-ataxia) — Source: Larimar Therapeutics